EFS MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • March 12th, 2021
This MASTER CLINICAL STUDY AGREEMENT (“Agreement”) is made effective as of the [NUMBER] day of [MONTH], [YEAR] (the “Effective Date”), and is by and between [SPONSOR NAME], a [ ] corporation, with offices at [ADDRESS] (“SPONSOR”) and [INSTITUTION NAME], a [ ] corporation with offices at [ADDRESS] (“Institution”).
EX-10.9 8 d772541dex109.htm MASTER CLINICAL STUDY AGREEMENT, MEMORIAL SLOAN- KETTERING CANCER CENTER [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment...Master Clinical Study Agreement • May 5th, 2020 • New York
This Master Clinical Study Agreement is entered into as of November 21, 2013 (the “Effective Date”), by and between Memorial Sloan-Kettering Cancer Center (“MSKCC”), a New York nonprofit corporation, and Juno Therapeutics, Inc. (“Sponsor”), a Delaware corporation.
ContractMaster Clinical Study Agreement • July 15th, 2009 • Texas
NOTE: Concept of Biological Samples *not* included in this Master CSA. Contact OGC if your Pfizer Protocol includes us sending biological samples to Pfizer.
MASTER CLINICAL STUDY AGREEMENT RÁMCOVÁ SMLOUVA O PROVEDENÍ KLINICKÉ STUDIEMaster Clinical Study Agreement • July 3rd, 2020
This Master Clinical Study Agreement (“Agreement”), effective as of the day of its publication in the Agreement Register according to section 9., subsection 9.1 hereto (“Effective Date”), sets forth the terms and conditions by and between Abbott Laboratories, a corporation registered under the laws of the state of Illinois, USA and its Affiliates acting through its Legal Representative in the European Union ST. JUDE MEDICAL COORDINATION CENTER BVBA, an Abbott company, a corporation organized under the laws of Belgium, with offices at The Corporate Village, Da Vincilaan, 11 Box F1, 1935 Zaventem, VAT: BE0888256714, lawfully represented by xxxxxxxxxxxxxxClinical Affairs (“Abbott”) and Nemocnice Na Homolce, a medical center located at Roentgenova 37/2, 150 30 Praha 5, Czech Republic, VAT: CZ00023884, represented by MUDr. Petr Polouček, MBA, director (“Institution”) to enable multiple clinical studies sponsored by Abbott (each, a “Study”) in relation to Abbott investigational or commercial
MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • June 30th, 2020
This Master Clinical Study Agreement (“Agreement”), effective as of the full execution hereof (“Effective Date”), sets forth the terms and conditions by and between Abbott Laboratories and its Affiliates (“Abbott”) and the following member health institutions of The University of Texas System (“UT System”):
MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • July 15th, 2009
THIS MASTER CLINICAL STUDY AGREEMENT is made and entered into as of the 22nd day of July, 2003 (the "Effective Date"), by and among Wyeth Pharmaceuticals Inc., sometimes acting through its division, Wyeth Research, having a business address at 555 East Lancaster Avenue, St. Davids, Pennsylvania 19087 ("Sponsor"), and each of The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, The University of Texas Health Center at Tyler, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center at Dallas (each an "Institution" and, collectively, the "Institutions"), each with an office and place of business as set forth on Schedule 1 hereto, and each a component institution of The University of Texas System, located at 201 West 7th Street, Austin TX 78701 ("System"), as governed by its Board of Regents ("Regents").
RESTATED AND AMENDED MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • December 18th, 2014 • Texas
(this “Master Agreement”) is effective November 24, 2014 (the “Effective Date”) between GlaxoSmithKline LLC (“GSK”), and all of the following member institutions (each an “Institution”, and collectively the “Institutions”) of The University of Texas System (“System”) located at 201 West 7th Street, Austin, TX, 78701, that is governed by its Board of Regents (“Board”):
MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • March 18th, 2015
This MASTER CLINICAL STUDY AGREEMENT (the “Master Agreement”) is made effective as of March 16, 2015 (the “Effective Date”) by and between
MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • July 15th, 2009 • Texas
THIS MASTER CLINICAL STUDY AGREEMENT (the “ Agreement”) is made and effective August 3, 2004 (the " Effective Date") between the following (and as further described in Exhibit B) component institutions of The University of Texas System ("System") located at 201 West 7th Street, Austin, Texas 78701, that is governed by its Board of Regents (“Board”): THE UNIVERSITY OF TEXAS HEALTH CENTER AT TYLER, THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON, THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS AND THE UNIVERSITY OF TEXAS AT AUSTIN (hereinafter collectively referred to as " Institution") and InterMune, Inc., a Delaware corporation (" InterMune"), having the respective addresses as set forth below. Each of Institution and InterMune may be referred to individually herein as a “ Party,” and jointly as th
MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • September 27th, 2016
This Master Clinical Study Agreement (“Agreement”), effective as of the date of full execution hereof (“Effective Date”) sets forth the terms and conditions by and between AbbVie Inc. (“AbbVie”) and The University of Texas Health Science Center at Houston; The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Tyler; The University of Texas Medical Branch at Galveston; The University of Texas Southwestern Medical Center; The University of Texas Rio Grande Valley, and The University of Texas at Austin (“Institution” or collectively, “Institutions”), each a member institution of The University of Texas System (“System”). In consideration of the mutual promises set forth herein, the parties hereto agree as follows:
AMENDED AND RESTATED MASTER CLINICAL STUDY AGREEMENT ABBOTT INITIATEDMaster Clinical Study Agreement • May 5th, 2020
This amended and restated master clinical study agreement (“Master Agreement”), effective as of the full execution hereof (“Effective Date”), sets forth the terms and conditions by and among Abbott Laboratories, an Illinois corporation having its principal place of business at 100 Abbott Park Road, Abbott Park, Illinois, 60064-3500 (“ABBOTT”) and each of The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at Tyler, The University of Texas Medical Branch at Galveston, The University of Texas Southwestern Medical Center, and The University of Texas at Austin (collectively referred to as “INSTITUTION”), each with an office and place of business as set forth on the signature line hereto, and each a component institution of The University of Texas System, located at 201 West 7th Street, Austin TX 78701, as governed by its Board of Regents.
AMENDED AND RESTATED MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • November 20th, 2015
Appendix A – Contact Persons and Address for each Institution Attachment A – Indemnification and Research Injury Policy
ContractMaster Clinical Study Agreement • July 20th, 2020
MASTER CLINICAL STUDY AGREEMENT RÁMCOVÁ SMLOUVA O PROVEDENÍ KLINICKÉ STUDIE This Master Clinical Study Agreement (“Agreement”), valid as of the full execution hereof (“Validity Date”) and effective as of the date of publishing in the Register of Contracts („Effective Date“), sets forth the terms and conditions by and between Abbott Laboratories and its Affiliates (“Abbott”) acting through its Legal Representative in the European Union ST. JUDE MEDICAL COORDINATION CENTER BVBA, an Abbott company, a corporation organized under the laws of Belgium, with offices at The Corporate Village, Da Vincilaan, 11 Box F1, 1935 Zaventem, Belgium, Tax ID: BE0888256714, lawfully represented by xxxxxxxxx and its Affiliates (“Abbott”) and Fakultni nemocnice Kralovske Vinohrady, a medical center located at Srobarova 1150/50, 100 34 Praha 10, Czech Republic, Company ID: 00064173, Tax ID: CZ00064173, established by decision of the Ministry of Health of 29 May 2012 under Ref. No.: MZDR 17266-III/2012, changi
AMENDMENT #2 TO THE MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • April 21st, 2020
AND AMaster Clinical Study Agreement • January 23rd, 2018
ZOLL Circulation located at 2000 Ringwood Ave., San Jose, CA 95131 , USA represented in the European Union by ZOLL Medical Deutschland GmbH, having a business address at Emil-Hoffmann Str. 13, 50996 Cologne, Germany VAT: DE203392290 - HRB 32891
SECOND MASTER CLINICAL STUDY AGREEMENTMaster Clinical Study Agreement • January 10th, 2018
This Second Master Clinical Study Agreement (“Agreement”), effective as of January 10, 2018 (“Effective Date”), sets forth the terms and conditions by and between Pharmacyclics LLC, an AbbVie Company and a Delaware Limited Liability Company (“Pharmacyclics”) and The University of Texas System for the benefit of Clinical Trials Xpress (as defined in Section 1 (c) below), The University of Texas Health Science Center at Houston; The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Tyler; The University of Texas Medical Branch at Galveston; The University of Texas Southwestern Medical Center; The University of Texas Rio Grande Valley, and The University of Texas at Austin (“Institution” or collectively, “Institutions”), each a member institution of The University of Texas System (“UT System”).
